Decitabine and Cedazuridine Uses, Dosage, Side Effects and Interactions
Inqovi
Inqovi was the first decitabine and cedazuridine product the FDA approved, in July 2020. No generic is listed as tablets.
Decitabine and cedazuridine is an oral combination cancer medicine used for certain bone marrow disorders (myelodysplastic syndromes, including chronic myelomonocytic leukemia) and, with venetoclax, for newly diagnosed acute myeloid leukemia in some adults.
Quick links
Ask Anything About Decitabine and CedazuridineType a question in your own words. Answered from its FDA label in seconds.Every other section of this page is in the dots on the left edge of your screen: point at one to see where it goes.Every other section of this page is one tap away: use the arrow tab on the left edge of your screen.
Decitabine and Cedazuridine in Short
- Drug class Nucleoside Metabolic Inhibitor How the FDA classifies it
What it treatsInqovi, the tablet form, is used in adults to treat myelodysplastic syndromes (MDS). These are bone marrow disorders in which the body does not make healthy blood cells. This includes previously treated and untreated MDS, and chronic myelomonocytic leukemia (CMML).
- How you get it Prescription only
- Comes asTablet (by mouth)
- Crushing or chewingSome forms are on our Do Not Crush list Listed: Decitabine-cedazuridine (tablet); Inqovi (tablet)
- Important safety informationWarnings and precautions Read the warnings and precautions for your exact product.
- Supplements and herbs17 interact 1 major, 7 moderate and 9 minor
- What Medicaid pays
- Inqovi (brand)$1,786.02 a tablet
- Generic launchFebruary 2034 Our estimate for the first generic of Inqovi
The Pharmacist’s Take
Inqovi pairs decitabine, which can help blood cells mature more normally, with cedazuridine, which stops the gut and liver breaking decitabine down, so this specialist cancer drug works as a tablet rather than an infusion for myelodysplastic syndromes (bone marrow disorders that make too few healthy blood cells), including CMML, and, with venetoclax, newly diagnosed acute myeloid leukemia; it has been on the market since about 2020, with no generic. Most people manage it, though tiredness, constipation and nausea are common and blood counts drop each cycle. Call your care team right away for fever, chills or unusual bleeding, since low counts can cause serious, sometimes fatal infections.
Key Takeaways From the HelloPharmacist Team
- Take it once daily for the first 5 days of each 28-day cycle, with no food for 2 hours before and after.
- Expect blood tests before every cycle, and a low count can mean a delayed cycle or fewer dosing days.
- Take any anti-nausea medicine your prescriber suggests before each dose, and call right away if you vomit or cannot keep doses down.
- Swallow the tablets whole without cutting or crushing, and follow the special handling and disposal instructions, since this is a hazardous drug.
Patient Information Guide for Decitabine and Cedazuridine
What It’s Used For
Decitabine and cedazuridine is used for these conditions in adults:
- Myelodysplastic syndromes (MDS): Inqovi treats previously treated and untreated MDS, including chronic myelomonocytic leukemia (CMML).
- Acute myeloid leukemia (AML): Inqovi is used with venetoclax for newly diagnosed AML in adults 75 or older, or those with conditions that rule out intensive induction chemotherapy.
How It Works
Decitabine is built into the DNA of cells and blocks an enzyme called DNA methyltransferase. This lowers DNA methylation, which may help restore normal control of how blood cells mature and multiply. In fast-dividing cells, it can also be toxic and cause cell death.
Cedazuridine blocks cytidine deaminase, an enzyme in the gut and liver that breaks down decitabine. This lets decitabine work when swallowed.
Drug Class
Drug Class
- Nucleoside Metabolic Inhibitor from decitabine
Detailed classifications and sources
The FDA sorts a drug’s active ingredient by how it works, what it does in the body and its chemical structure, and gives it one main drug class. Decitabine and Cedazuridine has two active ingredients, so each class says which one it comes from.
Drug Class
Established Pharmacologic Class (EPC)- Nucleoside Metabolic Inhibitor from decitabine
The main drug class the FDA gives it. It is the class named on the drug’s label.
How It Works
Mechanism of action (MoA)- Nucleic Acid Synthesis Inhibitors from decitabine
What it does at the smallest level, such as a receptor or enzyme it blocks or switches on.
What It Does in the Body
Physiologic effect (PE)None listed for Decitabine and Cedazuridine in the FDA’s index.
From our Patient Information GuideDecitabine is built into the DNA of cells and blocks an enzyme called DNA methyltransferase. This lowers DNA methylation, which may help restore normal control of how blood cells mature and multiply. In fast-dividing cells, it can also be toxic and cause cell death. Cedazuridine blocks cytidine deaminase, an enzyme in the gut and liver that breaks down decitabine. Read How Decitabine and Cedazuridine Works
A change it makes in how the body works.
Chemical Family
Chemical structure (CS)None listed for Decitabine and Cedazuridine in the FDA’s index.
The chemical family it belongs to, by its structure.
Drug Family
WHO ATC classification- Pyrimidine analogues from decitabine
How the World Health Organization groups it: by the part of the body it acts on and what it treats.
The classes are the FDA’s own words, from its index of drug labels, published in the National Library of Medicine’s RxClass. The description under What It Does in the Body is written by the HelloPharmacist team, not the FDA. Read the FDA’s definitions. The drug family is the World Health Organization’s ATC classification. Reference only, not medical advice.
Dosage
Inqovi is a tablet taken by mouth once daily for 5 days of each 28-day cycle.
- Take it on an empty stomach, 2 hours before or after eating.
- Swallow whole, at about the same time each day.
- With venetoclax, take Inqovi 2 hours before or after it.
- Missed a dose by less than 12 hours? Take it as soon as possible, then go back to your normal schedule. Your treatment period is extended by a day for each missed dose.
- If you vomit after a dose, do not take an extra one. Take your next scheduled dose.
Typical Doses
Your prescriber chooses your dose, so take it exactly as prescribed.
Myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML)
For adults · Recommended dose
Usual dose 1 tablet (35 mg decitabine and 100 mg cedazuridine) once a day
- 1 tablet (containing 35 mg decitabine and 100 mg cedazuridine) orally once daily on Days 1 through 5 of each 28-day cycle for a minimum of 4 cycles until disease progression or unacceptable toxicity
Good to know
Take on an empty stomach at least 2 hours before or 2 hours after eating
Newly diagnosed acute myeloid leukemia (AML)
Usual dose 1 tablet (35 mg decitabine and 100 mg cedazuridine) once a day
- 1 tablet (containing 35 mg decitabine and 100 mg cedazuridine) orally once daily on Days 1 through 5 of each 28-day cycle until disease progression or unacceptable toxicity
Good to know
Match Day 1 of Inqovi dosing with Day 1 of venetoclax dosing; take Inqovi 2 hours before or 2 hours after venetoclax
Special Situations
If side effects need a lower dose
Your doctor decides whether to lower your dose for side effects. Never change your dose on your own.
-
MDS or CMML, monotherapy, first dose reduction for myelosuppression
1 tablet orally once daily on Days 1 through 4
-
MDS or CMML, monotherapy, second dose reduction for myelosuppression
1 tablet orally once daily on Days 1 through 3
-
MDS or CMML, monotherapy, third dose reduction for myelosuppression
1 tablet orally once daily on Days 1, 3 and 5
-
AML, in combination with venetoclax, first dose reduction
1 tablet orally once daily on Days 1, 2 and 3
-
AML, in combination with venetoclax, second dose reduction
1 tablet orally once daily on Days 1, 3 and 5
-
AML, in combination with venetoclax, third dose reduction
1 tablet orally once daily on Days 1 and 2
Side Effects
Common side effects include:
Common side effects
- Tiredness
- Constipation
- Bleeding or easy bruising
- Muscle and joint pain
- Mouth sores or soreness
- Nausea and diarrhea
- Shortness of breath
- Low white blood cells, platelets and red blood cells (seen on blood tests)
- Shortness of breath, cough
- Rash, dizziness, headache
- Swelling and decreased appetite
When to get medical help
- Call your doctor right away for fever, chills or other signs of infection. Severe infections such as pneumonia and sepsis (a life-threatening blood infection) can be fatal.
- Tell your doctor about unusual bleeding or bruising, or feeling very weak or short of breath. These can signal low blood counts.
- Let your care team know right away if you vomit, have severe diarrhea, or can't keep your medicine down.
- Tell your doctor right away if you become pregnant or think you might be.
Warnings and Precautions
- Severe myelosuppression: low blood counts can lead to fatal infections and bleeding. Blood counts are checked before treatment and before each cycle.
- Serious infections: pneumonia and sepsis can occur, and some cases were fatal.
- Fetal harm: Inqovi can harm an unborn baby.
- Hazardous drug: special handling and disposal procedures apply.
Interactions
Few interactions are described, but one matters:
- Drugs broken down by cytidine deaminase: avoid combining, because cedazuridine can raise their levels and toxicity.
- Venetoclax: used together for AML. Take 2 hours apart.
- Food: it lowers decitabine absorption, so take on an empty stomach.
Interactions Listed in the FDA-Approved Label
From the Decitabine and Cedazuridine prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.
-
Drugs metabolized by cytidine deaminase (CDA)What happensCedazuridine inhibits the CDA enzyme, so coadministration may increase systemic exposure with potential for increased toxicity of these drugs.What to doAvoid coadministration of INQOVI with drugs that are metabolized by CDA.
Read the label’s full interactions text
7 DRUG INTERACTIONS Drugs Metabolized by Cytidine Deaminase: Avoid coadministration with INQOVI. 7.1 Effects of INQOVI on Other Drugs Drugs Metabolized by Cytidine Deaminase Cedazuridine is an inhibitor of the cytidine deaminase (CDA) enzyme. Coadministration of INQOVI with drugs that are metabolized by CDA may result in increased systemic exposure with potential for increased toxicity of these drugs. Avoid coadministration of INQOVI with drugs that are metabolized by CDA.
Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.
Before You Start
- Tell your doctor if you are pregnant or planning pregnancy. A pregnancy test is needed before starting.
- Use effective contraception: 6 months after the last dose for females, 3 months for males with female partners.
- Do not breastfeed during treatment and for 2 weeks after the last dose.
- Inqovi may impair male fertility.
- Safety in children has not been established.
- Tell your doctor about kidney problems. It has not been studied in severe kidney disease.
- Tell your doctor about any current infection.
Half-Life and How Your Body Processes It
Cedazuridine raises how much decitabine your body absorbs from a tablet. Over 5 days, decitabine exposure was about the same as with intravenous decitabine. A high-fat meal lowers decitabine absorption. Decitabine is mainly broken down by cytidine deaminase and has a half-life of about 1.5 hours. Cedazuridine's half-life is about 6.7 hours and it leaves the body through urine and stool.
Storage
Store at 20°C to 25°C (68°F to 77°F); excursions permitted from 15°C to 30°C (59°F to 86°F) .
Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI
Supplements and Herbs That Interact With Decitabine and Cedazuridine
From the licensed clinical database we use, rolled up per supplement, most serious first.17 supplements and herbal products have documented interactions with Decitabine and Cedazuridine in the licensed clinical database we use.
Most are manageable, but your pharmacist should know about everything you take, including vitamins and herbals.
- 1Major
- 7Moderate
- 9Minor
- ACTIVATED CHARCOALMajor
- COFFEE CHARCOALModerate
- EUROPEAN MANDRAKEModerate
- GLUCOMANNANModerate
- GUAR GUMModerate
- GUM ARABICModerate
- SLIPPERY ELMModerate
- TRAGACANTHModerate
Educational information from a licensed clinical database (Natural Medicines). See our data sources and update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.
Decitabine and Cedazuridine: Pharmacist Answers to Common Questions
Quick, plain-English answers to the questions patients ask most about Decitabine and Cedazuridine — the kind of thing our pharmacy team would talk through with you at the counter.
What is Inqovi used for?
How do I take Inqovi?
What happens if I miss a dose of Inqovi?
What side effects should I call my doctor about?
Is Inqovi safe during pregnancy or breastfeeding?
Can I take Inqovi with other medicines?
Is decitabine and cedazuridine available over the counter?
When was decitabine and cedazuridine first available?
What is the brand name of decitabine and cedazuridine?
What is the generic name of Inqovi?
What drug class is decitabine and cedazuridine?
What strengths does decitabine and cedazuridine come in?
How much does decitabine and cedazuridine cost?
Where can I read the decitabine and cedazuridine prescribing information (package insert)?
Can you crush decitabine and cedazuridine?
Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI
Ask Anything About Decitabine and Cedazuridine
Skip the scrolling. Ask in your own words and get an answer from Decitabine and Cedazuridine’s FDA label and our pharmacists’ own work.
Name another drug or a supplement in your question and we check both.
AI answers from FDA labels and our own records, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.How this works
- Sources: Decitabine and Cedazuridine’s FDA label, including the clinical studies it reports, and the label of any drug you name; our pharmacists’ own work, such as our Do Not Crush list and our published answers to readers’ questions; our pharmacy prices and the Natural Medicines supplement database.
- Written by AI: Answers are written by AI from those sources, and AI can make mistakes. Check what you read here with your doctor or pharmacist before you act on it.
- Reviewed afterward: Our pharmacy team reviews every question and answer afterward to check it for accuracy, and when we find an error, we correct how the box answers. Read more in How we use AI.
- Not medical advice. In an emergency, call 911, Poison Control at 1-800-222-1222, or 988.
More About Decitabine and Cedazuridine on HelloPharmacist
Still have a question? A licensed pharmacist answers for free, usually within a day.Decitabine and Cedazuridine Forms and Strengths (How It Comes)
Decitabine and Cedazuridine comes in 1 dose form, the tablet. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see Decitabine and Cedazuridine inactive ingredients by manufacturer.
Tablet
How this form is used
- Inqovi is used in adults with myelodysplastic syndromes, including chronic myelomonocytic leukemia.
- Inqovi is used with venetoclax for newly diagnosed acute myeloid leukemia in adults 75 or older, or those who can't have intensive chemotherapy.
- Inqovi is taken once daily on Days 1 through 5 of each 28-day cycle, on an empty stomach.
- Swallow Inqovi tablets whole. Do not cut, crush or chew them.
- Inqovi should not be swapped for intravenous decitabine within a cycle.
Decitabine and Cedazuridine on the U.S. Market: Products, Makers and Brands
How Decitabine and Cedazuridine appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
1 company lists 1 Decitabine and Cedazuridine product record with the FDA, mostly as tablet; the earliest marketing or approval year on record is 2020. The one brand name in the directory today is Inqovi; the rest are generics.
Also listed with the FDA, not a patient dose form: Unfinished tablet (1) — bulk drug substance and unfinished product sold to compounders and other manufacturers to finish, and multi-item kits. These aren’t counted in the dose-form total above.
How Widely Decitabine and Cedazuridine Is Used (Medicaid Data)
How many Decitabine and Cedazuridine prescriptions Medicaid paid for in Q1–Q4 2025, every brand, strength and form together. Medicaid is one program, so total U.S. use is higher.
How commonly is Decitabine and Cedazuridine prescribed? Of the 1,682 medications we measure, Decitabine and Cedazuridine ranks #1,580 by Medicaid prescriptions — more than 6% of them.
Utilization by Decitabine and Cedazuridine product
Pick a strength and form to see its own numbers. Brand and generic versions are counted together.
Other Decitabine and Cedazuridine products: packs and listings not matched to one strength and form
1 of 2 listed NDCs had Medicaid claims.
Dollars are what Medicaid paid before the rebates drug makers send back, so its real cost is lower.
Source: Medicaid State Drug Utilization Data (CMS), all states. 1 of the 2 listed Decitabine and Cedazuridine NDCs had Medicaid claims.
Compare Decitabine and Cedazuridine Products
A representative set of FDA-listed product records for Decitabine and Cedazuridine — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Tablet | ||||
| CEDAZURIDINE 100 mg/1; DECITABINE 35 mg | Oral | Taiho Pharmaceutical Co., Ltd. | NDA | View NDC → |
Showing 1 of 1 products — FDA National Drug Code Directory. See every product, package size and price: browse all 1 Decitabine and Cedazuridine NDCs →
Decitabine and Cedazuridine Side Effects Reported to the FDA (FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Decitabine and Cedazuridine — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Decitabine and Cedazuridine in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
Decitabine and Cedazuridine FDA Approval History
How Decitabine and Cedazuridine went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
Decitabine and Cedazuridine Recall History
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
The FDA’s enforcement reports list no Decitabine and Cedazuridine recalls since July 2021.
✅No Decitabine and Cedazuridine recalls on record since July 2021Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Nov 19, 2026.
Decitabine and Cedazuridine Supply and Shortage Status
Whether Decitabine and Cedazuridine is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
What Medicaid Pays for Decitabine and Cedazuridine
CMS’s weekly pharmacy survey (NADAC) has no price for Decitabine and Cedazuridine, so here is what state Medicaid programs paid for it over the four quarters through Q1 2026, before rebates. It is not your price at the counter.
| Form | Strength | Version | What Medicaid paid | |
|---|---|---|---|---|
| Tablet · Oral | CEDAZURIDINE 100 mg/1; DECITABINE 35 mg | Inqovi (brand) | $1,786.02 per tablet | NDC details & Medicaid use |
Source: CMS State Drug Utilization Data, total paid divided by units paid for across every state, for each strength’s packages.
Decitabine and Cedazuridine Brand Names
Decitabine and Cedazuridine has one brand name on record: Inqovi. A brand name is one company's name for the medicine; a generic has the same active ingredient under its generic name.
Who Makes Decitabine and Cedazuridine: Manufacturers and Labelers
One company lists Decitabine and Cedazuridine products with the FDA. By number of product records, the largest are Taiho Pharmaceutical Co., Ltd.. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.
Sources for This Decitabine and Cedazuridine Page
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How this page is built
HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Taiho Pharmaceutical Co., Ltd. is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →